MedTrace Logo

Degarelix in the Treatment of Endometriosis Recurrence

NCT01712763 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2024-03-06

No results posted yet for this study

Summary

The long acting GnRH antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

Conditions

  • Endometriosis

Interventions

DRUG

degarelix

180 women will be treated with degarlix 120 mg, in only one administration covering three months

DRUG

Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)

180 women will be treated with leuprolide acetate11.25 only once covering three months

Sponsors & Collaborators

  • Centre for Endocrinology and Reproductive Medicine, Italy

    lead NETWORK

Principal Investigators

  • MARCO SBRACIA, MD · Centre for Endocrinology and Reproductive Medicine, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Albania
  • Bulgaria
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712763 on ClinicalTrials.gov